Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

High-throughput epigenetic profiling immunoassays for accelerated disease research and clinical development

Wednesday, July 2, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a paper on high-throughput epigenetic profiling immunoassays, which aims to accelerate disease research and clinical development. Authored by a team of researchers, the study highlights the potential of these assays in improving prognostic evaluations, particularly in cancer testing. The findings are published in the Journal of Biological Chemistry.
Price reaction · baseline $15.358 (2025-07-01 close) · hit pre-market · 2 other VNRX headline(s) in the window, move may be shared
day 0 close
-2.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • High-throughput immunoassays can accelerate disease research.
  • The study contributes valuable insights to clinical development.
  • Published in a reputable journal, enhancing credibility.

Full Press Release Details

Paper titled: High-throughput epigenetic profiling immunoassays for accelerated disease research and clinical development
Priscilla Van den Ackerveken, Clotilde Hannart, Dorian Pamart, Robin Varsebroucq, Marion Wargnies, Olivia Thiry, Marie Lurkin, Séverine Vincent, Muriel Chapelier, Guillaume Rommelaere, and Marielle Herzog
Published in Journal of Biological Chemistry

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the published paper?

The paper focuses on high-throughput epigenetic profiling immunoassays for disease research.

Where was the research published?

The research was published in the Journal of Biological Chemistry.

Who are the authors of the study?

The study was authored by Priscilla Van den Ackerveken and colleagues.

What is the significance of the immunoassays?

These immunoassays aim to accelerate research and improve clinical development.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare epigenetic profiling immunoassays disease research clinical development
Last updated: Jul 2, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk